### Contents

**Highlights of This Issue  2009**

**FROM THE EDITOR-IN-CHIEF**

- **2011**  |  The Patient Impact Factor

**THE BEST OF MCT–10 YEARS**

- **2012**  |  Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer
  - David J. Bearss
- **2013**  |  First Report of Functional Chk1 siRNA Studies Applied to Drug Discovery
  - Zehan Chen
- **2015**  |  The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies
  - Dana Hu-Lowe, Nicoletta Brega, and Shem Patyna
- **2016**  |  PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235
  - Sauveur-Michel Maira
- **2017**  |  Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions
  - Florence I. Raynaud and Paul Workman
- **2019**  |  The Discovery of Lapatinib (GW572016)
  - David Rusnak and Tona M. Gilmer
- **2020**  |  Methylation Profiling of Lung Cancer: A Decade of Progress
  - Shinichi Toyooka and Adi F. Gazdar
- **2021**  |  MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between ‘-omic’ and Hypothesis-Driven Research
  - John N. Weinstein
- **2022**  |  Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer
  - Xueyan Wang, Gerald McMahon, and Kenneth E. Lipson
- **2024**  |  Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models
  - James G. Christensen
- **2025**  |  Lapatinib: Functional Genomics Study Leads to Insights into Mechanism of Action
  - Tona M. Gilmer
- **2026**  |  Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST
  - Andrew K. Godwin
- **2028**  |  The Importance of PK/PD Data—Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics
  - Rakesh Kumar and Benjamin Suttle
- **2029**  |  Bortezomib: Understanding the Mechanism of Action
  - Bilal Piperdi, Yi-He Ling, Leonard Liebes, Franco Muggia, and Roman Perez-Soler
- **2031**  |  Starting with the ABCs: Akt in Breast Cancer
  - Kip A. West and Phillip A. Dennis
- **2032**  |  Cell Line Models Identify Different Sensitivity of Mutant Forms of c-KIT to Kinase Inhibitory Drugs and Predict the Response of Patients to Therapy
  - Leonie K. Ashman
- **2034**  |  Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
  - Teru Hideshima, Paul G. Richardson, and Kenneth C. Anderson
THERAPEUTIC DISCOVERY

2043 Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Kruppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Agnieszka B. Bialkowska, Melissa Crisp, Thomas Bannister, Yuanjun He, Sarwat Chowdhury, Stephan Schurer, Peter Chase, Timothy Spencer, Franck Madoux, Chenlu Tian, Peter Hodder, Daniel Zaharevitz, and Vincent W. Yang

2052 Discovery and Evaluation of Inhibitors of Human Ceramidase
Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, and Charles D. Smith

2062 Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells
Carolyn M. Klinge, Brandie N. Radde, Yoannis Inbert-Fernandez, Yun Teng, Margarita M. Ivanova, Sabra M. Abner, and Alexandra L. Martin

2072 A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, and Malcolm Finlayson

2083 Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks
Ioannis Prassas, George S. Karagiannis, Ihor Batruch, Apostolos Dimitromanolakis, Alessandro Dattu, and Eleftherios P. Diamandis

PRECLINICAL DEVELOPMENT

2094 Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways
Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, and Razelle Kurzrock

2104 Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, and Eileen A. Friedman

2115 The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

2124 Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

2135 Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

2146 3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis
Dharmalingam Subramaniam, Nathan D. Nichols, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen, and Shrikant Anant

2157 Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger, Christian Moser, Claus Hellerbrand, Maria E. Mycielska, Gabriel Glockzin, Hans J. Schlitt, Edward K. Geissler, Oliver Stodtzing, and Sven A. Lang
Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization

Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Julie Stewart, Wayne Blosser, James Cook, Debra Young, Xiang Ye, Glenn Evans, Kelly Credille, Darryl Ballard, Lysiane Huber, Andrew Capen, Marcio Chedid, Robert Ilaria, Jr., Michele C. Smith, and Louis Stancato

Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation

Anja Uhmann, Hannah Niemann, Bénine Lammering, Cornelia Henkel, Ina Heß, Frauke Nitzki, Anne Fritsch, Nicole Prüfer, Albert Rosenberger, Christian Dullin, Anke Schraepfer, Julia Reifenberger, Stefan Schweyer, Torsten Pletsch, Frank Strutz, Walter Schulz-Schaefeer, and Heidi Hahn

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity


A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaoqen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng, and Denis J. McCann

Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

About the Cover

Met kinase homology model with its inhibitor, SU11271, docked in the ATP binding site. The cover image was selected from an article previously published in Molecular Cancer Therapeutics, which was chosen in celebration of the 10th anniversary of the journal. For details, see the commentary by Wang and colleagues on page 2022.
Molecular Cancer Therapeutics

10 (11)


| Updated version | Access the most recent version of this article at: http://mct.aacrjournals.org/content/10/11 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |